Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab Subcutaneous (SC) infusion;   Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC infusion;   Drug: Daratumumab Intravenous (IV) infusion
    Sponsor:   Janssen Research & Development, LLC
    Not yet recruiting - verified August 2015

  • Condition:   Haematological Malignancy
    Intervention:   Drug: SAR650984
    Sponsor:   Sanofi
    Recruiting - verified August 2015

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Wild-type Reovirus
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Not yet recruiting - verified July 2015

  • Conditions:   Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
    Interventions:   Biological: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Biological: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting - verified July 2015

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Leflunomide;   Other: Pharmacological Study
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Palifermin;   Drug: Panobinostat;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Dexamethasone acetate;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Procedure: Stem Cell Transplant
    Sponsors:   M.D. Anderson Cancer Center;   Novartis Pharmaceuticals
    Not yet recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Ixazomib
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Not yet recruiting - verified August 2015

  • Conditions:   Indolent Plasma Cell Myeloma;   Plasma Cell Myeloma;   Smoldering Plasma Cell Myeloma
    Interventions:   Biological: Anakinra;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Placebo
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Not yet recruiting - verified July 2015

  • Condition:   Hemophilia B
    Intervention:   Genetic: SPK-9001
    Sponsors:   Spark Therapeutics;   Pfizer
    Not yet recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Daratumumab
    Sponsor:   Janssen Research & Development, LLC
    Available - verified August 2015

  • Conditions:   Vasculitis;   Systemic Vasculitis;   Behcet's Disease;   CNS Vasculitis;   Cryoglobulinemic Vasculitis;   Eosinophilic Granulomatosis;   Temporal Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa (PAN);   Takayasu's Arteritis;   Urticarial Vasculitis
    Intervention:   Other: online questionnaire
    Sponsors:   University of South Florida;   University of Western Ontario, Canada;   University of Pennsylvania;   University of Toronto
    Recruiting - verified June 2015

  • Condition:   Von Willebrands Disease
    Intervention:  
    Sponsors:   Jonathan Roberts;   Blood Center of Wisconsin
    Not yet recruiting - verified June 2015

  • Conditions:   Lyphoma, B-Cell;   Leukemia, B-cell;   Multiple Myeloma;   Hematologic Malignancies
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: MLN9708;   Drug: Dexamethasone;   Drug: Bendamustine
    Sponsor:   Parameswaran Hari
    Not yet recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: ABBV-838
    Sponsor:   AbbVie
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Allogeneic HSCT;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Bortezomib;   Drug: Ixazomib;   Drug: Placebo
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Conditions:   Multiple Myeloma;   Myeloma-Multiple
    Interventions:   Biological: Tocilizumab;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Filgrastim
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsors:   Dana-Farber Cancer Institute;   Millennium Pharmaceuticals, Inc.;   Celgene Corporation
    Not yet recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: MPDL3280A
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2015

  • Condition:   Waldenstrom's Macroglobulinemia
    Intervention:   Drug: GS-1101
    Sponsors:   Dana-Farber Cancer Institute;   Gilead Sciences
    Not yet recruiting - verified May 2015

  • Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Acute Myelogenous Leukemia;   Acute Lymphoid Leukemia;   Leukemia, Acute Lymphoblastic;   Multiple Myeloma;   Myelofibrosis
    Intervention:   Other: Laboratory Assay for genetic testing
    Sponsors:   University of Florida;   Cellworks Group, Inc.
    Recruiting - verified July 2015

  • Condition:   Myeloproliferative Diseases
    Interventions:   Drug: Nivolumab;   Behavioral: Questionnaire;   Behavioral: Phone Call
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone
    Sponsor:   Onyx Therapeutics, Inc.
    Recruiting - verified August 2015

  • Conditions:   Polycythemia Vera;   Essential Thrombocythemia
    Interventions:   Drug: RG7388;   Drug: Pegasys
    Sponsors:   John Mascarenhas;   Genentech, Inc.;   Roche Pharma AG
    Recruiting - verified April 2015

  • Condition:   HIV
    Interventions:   Drug: vorapaxar;   Drug: Placebo
    Sponsors:   Kirby Institute;   National Institute of Allergy and Infectious Diseases (NIAID);   University of Minnesota - Clinical and Translational Science Institute;   University of Melbourne;   Merck Sharp & Dohme Corp.
    Not yet recruiting - verified March 2015

  • Condition:   Relapsed Multiple Myeloma
    Interventions:   Drug: ATRA;   Drug: Celecoxib;   Drug: Itraconazole
    Sponsor:   University of Iowa
    Recruiting - verified May 2015

  • Conditions:   Hemophilia A;   Hemophilia B
    Interventions:   Biological: rFVIIIFc;   Biological: rFIXFc;   Drug: non-Fc FVIII replacement products;   Drug: non-Fc FIX replacement products
    Sponsors:   Biogen;   Swedish Orphan Biovitrum
    Recruiting - verified July 2015

  • Conditions:   HHT;   Hereditary Hemorrhagic Telangiectasia;   Epistaxis;   Nose Bleeds;   Nasal Bleeding
    Intervention:   Drug: Bevacizumab
    Sponsor:   Stanford University
    Recruiting - verified March 2015

  • Condition:   Waldenstrom's Macroglobulinemia
    Interventions:   Drug: Ixazomib;   Drug: Dexamethasone;   Drug: Rituximab
    Sponsors:   Dana-Farber Cancer Institute;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified April 2015

  • Conditions:   Plasma Cell Myeloma;   Residual Disease
    Interventions:   Drug: Ixazomib Citrate;   Drug: Lenalidomide;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: ACY-241;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsor:   Acetylon Pharmaceuticals Incorporated
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Dexamethasone
    Sponsor:   Boston Medical Center
    Not yet recruiting - verified February 2015

  • Condition:   Blood Coagulation Disorders
    Intervention:   Device: ROTEM sigma
    Sponsor:   Tem Innovations GmbH
    Recruiting - verified May 2015

  • Condition:   Hermansky Pudlak Syndrome
    Interventions:   Other: Pulmonary function test;   Other: Chest CT;   Other: Sample collection
    Sponsors:   Vanderbilt University;   University of South Florida;   National Institutes of Health (NIH)
    Recruiting - verified February 2015

  • Conditions:   Metastatic Cancers;   Multiple Myeloma;   Vertebral Fracture
    Interventions:   Procedure: Vertebroplasty;   Radiation: Radiotherapy
    Sponsor:   University of Arizona
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Ixazomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Eric Winer, MD;   Rhode Island Hospital;   The Miriam Hospital
    Not yet recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Elotuzumab
    Sponsor:   Bristol-Myers Squibb
    Available - verified August 2015

  • Condition:   Congenital Heart Disease
    Intervention:   Other: Perioperative blood samples collection
    Sponsor:   Children's Hospital Boston
    Not yet recruiting - verified January 2015

  • Conditions:   Non-hodgkin Lymphoma;   Multiple Myeloma;   Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Richter's Syndrome;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: ACP-196;   Drug: Pembrolizumab
    Sponsor:   Acerta Pharma BV
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: VLX1570 and dexamethasone
    Sponsor:   Vivolux AB
    Recruiting - verified March 2015

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Hemophilia A;   Factor VIII Deficiency;   Hemophilia;   Hemophilia B;   Factor IX Deficiency
    Intervention:   Procedure: Peripheral Vein Blood draw
    Sponsor:   Children's Mercy Hospital Kansas City
    Recruiting - verified January 2015

  • Conditions:   Malignant Solid Tumour;   Carcinoma, Non-Small-Cell Lung;   Stomach Neoplasms;   Urothelial Carcinoma;   Endometrial Neoplasms;   Multiple Myeloma;   MPN
    Intervention:   Drug: INCB054828
    Sponsor:   Incyte Corporation
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone;   Procedure: Stem Cell Mobilization
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Selinexor;   Drug: Dexamethasone
    Sponsor:   Karyopharm Therapeutics, Inc
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Selinexor;   Drug: Dexamethasone;   Drug: Bortezomib;   Drug: Pomalidomide
    Sponsor:   Karyopharm Therapeutics, Inc
    Not yet recruiting - verified August 2015

  • Conditions:   Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
    Interventions:   Biological: Incomplete Freund's Adjuvant;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Sargramostim;   Biological: SVN53-67/M57-KLH Peptide Vaccine
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Drug: Lenalidomide;   Drug: MK-3475
    Sponsors:   University of Michigan Cancer Center;   Medical College of Wisconsin
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Onyx Therapeutics, Inc.
    Recruiting - verified August 2015

  • Conditions:   Non-hodgkin Lymphoma;   Multiple Myeloma;   B-All
    Interventions:   Drug: ACP-196 and ACP-319;   Drug: ACP-196 and ACP-319
    Sponsor:   Acerta Pharma BV
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Lenalidomide
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Inflammation;   Coagulation;   HIV Infection
    Interventions:   Drug: Edoxaban 30mg daily;   Drug: Matching placebo
    Sponsor:   Minneapolis Medical Research Foundation
    Not yet recruiting - verified March 2015

  • Condition:   Smoldering Multiple Myeloma (SMM)
    Interventions:   Drug: daratumumab;   Drug: daratumumab;   Drug: daratumumab
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: SAR650984;   Drug: Carfilzomib
    Sponsor:   University of California, San Francisco
    Recruiting - verified June 2015

  • Conditions:   Multiple Myeloma;   Plasma Cell Leukemia
    Intervention:   Drug: Bendamustine
    Sponsor:   Thomas Jefferson University
    Not yet recruiting - verified April 2015

  • Conditions:   Type I Plasminogen Deficiency;   Hypoplasminogenemia
    Intervention:   Biological: Plasminogen (Human) Intravenous
    Sponsor:   ProMetic BioTherapeutics, Inc
    Recruiting - verified December 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Ixazomib;   Drug: Placebo
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified July 2015

  • Condition:   Hemophilia A
    Intervention:   Other: Colorado Adult Joint Assessment Evaluation
    Sponsor:   Bayer
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Intervention:   Biological: TAA-specific CTLs
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Prednisone;   Drug: Methylprednisolone
    Sponsors:   Oncotherapeutics;   Onyx Therapeutics, Inc.
    Recruiting - verified November 2014

  • Condition:   Von Willebrand Disease
    Intervention:   Biological: Recombinant von Willebrand Factor (rVWF)
    Sponsors:   Baxalta US Inc.;   Baxter Innovations GmbH
    Recruiting - verified April 2015

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Immunodeficiency;   Myelodysplastic Syndrome
    Intervention:  
    Sponsors:   Fred Hutchinson Cancer Research Center;   University of Washington;   Seattle Children's Hospital
    Recruiting - verified June 2015

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: rituximab;   Drug: lenalidomide;   Drug: romidepsin;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Not yet recruiting - verified October 2014

  • Condition:   Congenital Afibrinogenaemia
    Intervention:   Biological: Human Plasma-Derived Fibrinogen Concentrate
    Sponsor:   Instituto Grifols, S.A.
    Not yet recruiting - verified October 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: I-131-CLR1404;   Drug: dexamethasone
    Sponsor:   Cellectar Biosciences, Inc.
    Recruiting - verified August 2015

  • Conditions:   Multiple Myeloma;   Plasma Cell Disorder
    Interventions:   Other: Tai Chi;   Other: Education
    Sponsors:   Mayo Clinic;   Arizona State University
    Recruiting - verified May 2015

  • Conditions:   Multiple Myeloma;   Myeloma, Multiple;   Myeloma-Multiple
    Intervention:  
    Sponsors:   Michael A. Thompson, MD, PhD;   Vince Lombardi Cancer Clinic 
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: MK-3475;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsors:   Ashraf Badros;   Merck Sharp & Dohme Corp.
    Recruiting - verified January 2015

  • Condition:   Immune Thrombocytopenic Purpura
    Intervention:   Drug: BMS-986004
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified August 2015

  • Condition:   Immune Thrombocytopenia (ITP)
    Intervention:   Drug: Romiplostim
    Sponsor:   Amgen
    Recruiting - verified July 2015

  • Conditions:   Monoclonal Gammopathy of Undetermined Significance (MGUS);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic-Myeloproliferative Diseases;   Hematological Malignancies;   B-cell Malignancy, Low-grade;   Myelodysplastic Syndrome With Low-grade Lesions;   IgG Monoclonal Gammopathy of Uncertain Significance;   Smoldering Multiple Myeloma;   Waldenstrom Macroglobulinemia
    Intervention:  
    Sponsors:   Dana-Farber Cancer Institute;   The Leukemia and Lymphoma Society
    Recruiting - verified August 2015

  • Condition:   Severe Haemophilia A
    Intervention:   Biological: Human cl rhFVIII
    Sponsor:   Octapharma
    Recruiting - verified October 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: LDE225;   Drug: Bortezomib
    Sponsors:   SCRI Development Innovations, LLC;   Novartis
    Recruiting - verified August 2015

  • Conditions:   Smoldering Myeloma;   Smoldering Multiple Myeloma
    Interventions:   Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb;   Celgene Corporation
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Elotuzumab;   Drug: Lirilumab;   Drug: Urelumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified April 2015

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
    Interventions:   Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
    Sponsors:   Memorial Hospital of Rhode Island;   Spectrum Pharmaceuticals, Inc
    Not yet recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Interventions:   Biological: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsors:   Washington University School of Medicine;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified August 2015

  • Conditions:   Acute Myelogenous Leukemia (AML);   Multiple Myeloma (MM);   Myelodysplastic Syndrome (MDS);   Smoldering Multiple Myeloma (sMM)
    Interventions:   Drug: Sargramostim;   Drug: BB-MPI-03;   Drug: Montanide
    Sponsor:   Benovus Bio, Inc.
    Recruiting - verified July 2015

  • Conditions:   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: everolimus;   Drug: bendamustine hydrochloride
    Sponsors:   University of California, Davis;   Novartis
    Recruiting - verified September 2014

  • Condition:   Hemophilia A
    Intervention:   Biological: rFVIIIFc
    Sponsors:   Biogen;   Swedish Orphan Biovitrum
    Recruiting - verified May 2015

  • Conditions:   Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
    Interventions:   Drug: CC-486;   Drug: Vidaza
    Sponsor:   Celgene Corporation
    Recruiting - verified August 2015

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: Bendamustine hydrochloride;   Drug: Bortezomib;   Drug: Dexamethasone
    Sponsor:   Thomas Jefferson University
    Recruiting - verified April 2015

  • Condition:   Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
    Intervention:   Drug: Recombinant ADAMTS13
    Sponsor:   Baxalta US Inc.
    Recruiting - verified January 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Sotatercept;   Drug: Placebo
    Sponsors:   Rebecca Silbermann;   Celgene Corporation
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Biological: Bortezomib;   Drug: G-CSF
    Sponsors:   Washington University School of Medicine;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Conditions:   Myeloma, Plasma-Cell;   Myeloma-Multiple
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Anti-BCMA CAR T cells
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Condition:   Congenital Fibrinogen Deficiency
    Intervention:   Drug: Octafibrin
    Sponsor:   Octapharma
    Recruiting - verified October 2014

  • Condition:   Multiple Myeloma (MM)
    Intervention:   Drug: ACP-196
    Sponsor:   Acerta Pharma BV
    Recruiting - verified June 2015

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan;   Drug: Prednisone;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Dietary Supplement: Ascorbic acid;   Drug: PLD;   Drug: Lenalidomide
    Sponsors:   Oncotherapeutics;   Millennium: The Takeda Oncology Company
    Recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsor:   Indiana University
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Panobinostat
    Sponsor:   Novartis Pharmaceuticals
    Available - verified June 2015

  • Condition:   Telangiectasia, Hereditary Hemorrhagic
    Interventions:   Drug: Pazopanib;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting - verified July 2015

  • Condition:   Hemophilia B
    Intervention:   Biological: rFIXFc
    Sponsors:   Biogen;   Swedish Orphan Biovitrum
    Recruiting - verified July 2015

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: selinexor;   Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: questionnaire administration
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Conditions:   Hemophilia A;   Hemophilia B
    Interventions:   Biological: ADVATE (Antihemophilic Factor [Recombinant]);   Biological: RIXUBIS (Coagulation Factor IX [Recombinant])
    Sponsor:   Baxalta US Inc.
    Recruiting - verified April 2015

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Intervention:   Biological: CM-CS1 T-cell infusion
    Sponsors:   Celdara Medical, LLC;   Dana-Farber Cancer Institute;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Velcade;   Drug: Melphalan;   Drug: Prednisone;   Drug: Daratumumab
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified August 2015

  • Condition:   Severe Hemophilia A
    Intervention:   Drug: Long-acting recombinant factor VIII Fc fusion protein
    Sponsor:   University of Pittsburgh
    Not yet recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Selinexor;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Dexamethasone
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Karyopharm Therapeutics, Inc
    Recruiting - verified June 2015

  • Condition:   Waldenström Macroglobulinemia (WM)
    Intervention:   Drug: ACP-196
    Sponsor:   Acerta Pharma BV
    Recruiting - verified September 2014

  • Conditions:   Hemophilia A;   Severe Hemophilia A
    Intervention:   Biological: rVIII‑SingleChain
    Sponsor:   CSL Behring
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MV-NIS
    Sponsor:   University of Arkansas
    Recruiting - verified March 2015

  • Conditions:   Multiple Myeloma;   Autologous Stem Cell Transplant
    Interventions:   Drug: Ixazomib Citrate;   Drug: Placebo
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2015

  • Conditions:   Heart Failure;   Multiple Myeloma
    Intervention:  
    Sponsors:   Daniel Lenihan;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified December 2014

  • Conditions:   Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
    Interventions:   Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Ajai Chari;   Celgene Corporation
    Recruiting - verified June 2015

  • Conditions:   Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
    Intervention:   Drug: MLN9708
    Sponsors:   Northside Hospital, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2015

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: bendamustine hydrochloride;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsors:   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MLN9708
    Sponsors:   SCRI Development Innovations, LLC;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2015

  • Condition:   Waldenström's Macroglobulinemia
    Interventions:   Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
    Sponsors:   Pharmacyclics;   Janssen Research & Development, LLC
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: ACY-1215 in combination with pomalidomide and dexamethasone
    Sponsor:   Acetylon Pharmaceuticals Incorporated
    Recruiting - verified June 2015

  • Conditions:   Multiple Myeloma;   Bone Marrow Failure Syndromes;   Hemoglobinopathies;   AML;   ALL;   Myeloid Leukemia, Chronic;   NHL;   HL;   MDS;   Amyloidosis;   Myelofibrosis
    Interventions:   Drug: Tacrolimus;   Drug: Anti-thymocyte globulin;   Procedure: Kidney transplant;   Drug: Bone marrow transplant from a related donor;   Radiation: Total body irradiation 400 centigray (200 cGy X 2)
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: CPI-0610
    Sponsors:   Constellation Pharmaceuticals;   The Leukemia and Lymphoma Society
    Recruiting - verified February 2015

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Waldenström Macroglobulinemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
    Interventions:   Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Cohort 1: Carfilzomib 15 mg/m2;   Drug: Cohort 2: Carfilzomib 20 mg/m2;   Drug: Cohort 2b: Carfilzomib 20 mg/m2;   Drug: Cohort 3b: Carfilzomib 27 mg/m2
    Sponsor:   Spectrum Health Hospitals
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Trametinib
    Sponsor:   University of Arkansas
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: VELCADE (Bortezomib);   Drug: Dexamethasone
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified August 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Essential Thrombocythemia;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndrome;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Erismodegib;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Acute Myeloid Leukemia;   Hematologic Malignancies;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma,;   Multiple Myeloma;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelofibrosis;   Myeloproliferative Syndrome
    Interventions:   Radiation: total marrow irradiation;   Drug: fludarabine phosphate;   Drug: busulfan;   Procedure: myeloid progenitor cell transplantation;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MEL-CFZ-TD-PACE
    Sponsors:   University of Arkansas;   Onyx Pharmaceuticals
    Recruiting - verified April 2015

  • Conditions:   Refractory Plasma Cell Myeloma;   Recurrent Plasma Cell Myeloma
    Interventions:   Drug: ixazomib citrate;   Drug: dexamethasone;   Drug: pomalidomide;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Congenital Bleeding Disorder;   Haemophilia B
    Intervention:   Drug: nonacog beta pegol
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified July 2015

  • Conditions:   Solid Tumors;   Multiple Myeloma;   Non-Hodgkins Lymphoma
    Intervention:   Drug: DCR-MYC
    Sponsor:   Dicerna Pharmaceuticals, Inc.
    Recruiting - verified August 2015

  • Condition:   ATIII Deficiency
    Interventions:   Drug: Anti-thrombin III;   Other: Placebo
    Sponsors:   Duke University;   Grifols Biologicals Inc.
    Recruiting - verified August 2015

  • Conditions:   Primary Myelofibrosis (PMF),;   Post-polycythemia Vera (Post-PV);   Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
    Interventions:   Drug: Momelotinib;   Drug: Best Available Therapy (BAT)
    Sponsor:   Gilead Sciences
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Granix;   Drug: High dose melphalan (HDR);   Procedure: Autologous Stem Cell Transplant (ASCT)
    Sponsor:   Washington University School of Medicine
    Recruiting - verified May 2015

  • Conditions:   Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
    Interventions:   Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone
    Sponsors:   Triphase Research and Development I Corporation;   Celgene Corporation
    Recruiting - verified May 2015

  • Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
    Intervention:   Drug: TG-0054 combined with G-CSF
    Sponsor:   TaiGen Biotechnology Co., Ltd.
    Recruiting - verified April 2015

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Biological: Wild-type Reovirus
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   End Stage Renal Failure on Dialysis;   Complication of Dialysis;   Blood Coagulation Disorders
    Intervention:  
    Sponsors:   Marie Hogan;   NxStage Medical
    Recruiting - verified April 2015

  • Condition:   Waldenstrom's Macroglobulinemia
    Interventions:   Drug: IMO-8400;   Drug: IMO-8400;   Drug: IMO-8400
    Sponsor:   Idera Pharmaceuticals, Inc.
    Recruiting - verified April 2015

  • Condition:   Leukemia
    Interventions:   Drug: LCL-161;   Behavioral: Questionnaires;   Other: Phone Calls
    Sponsors:   M.D. Anderson Cancer Center;   Novartis
    Recruiting - verified July 2015

  • Conditions:   Blood Coagulation Disorders;   Trauma;   Acute Coagulopathy
    Intervention:   Other: Blood collection
    Sponsor:   University of Rochester
    Recruiting - verified March 2015

  • Condition:   Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Dexamethasone
    Sponsors:   M.D. Anderson Cancer Center;   Onyx Therapeutics, Inc.
    Recruiting - verified July 2015

  • Conditions:   Multiple Myeloma;   Lymphoma, Non-Hodgkin
    Interventions:   Drug: XM02 Filgrastim;   Drug: Filgrastim;   Procedure: Apheresis;   Drug: Plerixafor
    Sponsor:   Washington University School of Medicine
    Recruiting - verified May 2015

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: erismodegib;   Drug: lenalidomide
    Sponsor:   Mayo Clinic
    Recruiting - verified June 2015

  • Condition:   Immune Thrombocytopenic Purpura
    Intervention:   Drug: Fostamatinib Disodium
    Sponsor:   Rigel Pharmaceuticals
    Recruiting - verified August 2015

  • Condition:   Immune Thrombocytopenic Purpura
    Interventions:   Drug: Fostamatinib Disodium 100mg;   Drug: Placebo;   Drug: Fostamatinib Disodium 150mg
    Sponsor:   Rigel Pharmaceuticals
    Recruiting - verified August 2015

  • Conditions:   Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
    Interventions:   Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Yvonne Efebera;   CureTech Ltd
    Recruiting - verified March 2015

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Intervention:   Biological: ALT-803
    Sponsors:   Altor Bioscience Corporation;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Hemophilia
    Intervention:  
    Sponsor:   Oregon Health and Science University
    Recruiting - verified April 2015

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: nab-paclitaxel
    Sponsors:   New York University School of Medicine;   Celgene Corporation
    Recruiting - verified March 2015

  • Conditions:   Adult Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma Recurrent;   Lymphoma, Follicular;   Marginal Zone B-Cell Lymphoma;   Malignant Lymphoma - Lymphoplasmacytic;   Waldenstrom Macroglobulinemia;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   T-Cell Lymphoma
    Intervention:   Drug: Doxycycline
    Sponsor:   University of Rochester
    Recruiting - verified July 2015

  • Condition:   Wiskott-Aldrich Syndrome
    Intervention:  
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium;   Rare Diseases Clinical Research Network
    Recruiting - verified June 2015

  • Conditions:   Non-Hodgkin's Lymphoma (NHL);   Multiple Myeloma;   Waldenstrom's Macroglobulinemia (WM);   Diffuse Large B-cell Lymphoma (DLBCL),;   Other B-cell NHL Subtypes, Including WM;   T-cell NHL
    Intervention:   Drug: CB-839
    Sponsor:   Calithera Biosciences, Inc
    Recruiting - verified February 2015

  • Conditions:   Multiple Myeloma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Meloxicam;   Drug: Filgrastim
    Sponsors:   Indiana University;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: GSK2857916
    Sponsor:   GlaxoSmithKline
    Recruiting - verified August 2015

  • Conditions:   Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
    Interventions:   Drug: Pacritinib;   Drug: Best Available Therapy
    Sponsor:   CTI BioPharma
    Recruiting - verified June 2015

  • Conditions:   Liver Surgery;   Liver Dysfunction;   Coagulopathy;   Cardiac Surgery
    Intervention:   Biological: octaplas
    Sponsor:   Octapharma
    Recruiting - verified August 2015

  • Condition:   Hemophilia B
    Intervention:   Biological: rIX-FP
    Sponsor:   CSL Behring
    Recruiting - verified August 2015

  • Conditions:   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: PI3K inhibitor BKM120;   Biological: rituximab;   Other: Pharmacodynamics;   Other: Correlative studies
    Sponsors:   Kami Maddocks;   Novartis
    Recruiting - verified April 2015

  • Conditions:   Coagulopathy;   Endstage Liver Disease
    Interventions:   Biological: Octaplas™;   Biological: Plasma
    Sponsor:   Octapharma
    Recruiting - verified August 2015

  • Conditions:   Solid Tumors;   Multiple Myeloma
    Intervention:   Drug: TAS-120
    Sponsor:   Taiho Oncology, Inc.
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Radiation: Total Marrow Irradiation;   Procedure: Autologous Transplant;   Drug: Melphalan;   Drug: Filgrastim (G-CSF)
    Sponsor:   University of Illinois at Chicago
    Recruiting - verified May 2015

  • Conditions:   Multiple Myeloma, Relapsed;   Multiple Myeloma, Refractory to Standard Treatment
    Interventions:   Radiation: Total Marrow Irradiation;   Drug: Melphalan;   Drug: Filgrastim (G-CSF)
    Sponsor:   University of Illinois at Chicago
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Biological: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsors:   Merck Sharp & Dohme Corp.;   Celgene Corporation
    Recruiting - verified August 2015

  • Conditions:   Myeloma, Multiple;   Paraproteinemias;   Hematologic Neoplasms
    Intervention:  
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting - verified March 2015

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis
    Sponsors:   Attaya Suvannasankha;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Palbociclib;   Drug: Dexamethasone;   Drug: Lenalidomide
    Sponsors:   Weill Medical College of Cornell University;   Celgene Corporation;   Pfizer
    Recruiting - verified May 2015

  • Condition:   Purpura, Thrombocytopenic, Idiopathic
    Intervention:   Drug: BI 655064
    Sponsor:   Boehringer Ingelheim
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bendamustine;   Drug: Carfilzomib;   Drug: Dexamethasone
    Sponsor:   Suzanne Lentzsch, MD
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Velcade;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Thalidomide;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Montelukast
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
    Sponsor:   Acetylon Pharmaceuticals Incorporated
    Recruiting - verified June 2015

  • Condition:   Severe Hemophilia A
    Intervention:   Biological: Human-cl rhFVIII
    Sponsor:   Octapharma
    Recruiting - verified January 2015

  • Condition:   Multiple Myeloma
    Interventions:   Biological: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs);   Other: Standard of care
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Rockefeller University
    Recruiting - verified April 2015

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
    Interventions:   Biological: PRM-151;   Drug: Ruxolitinib
    Sponsor:   Promedior, Inc.
    Recruiting - verified April 2015

  • Condition:   Immune Thrombocytopenia
    Intervention:   Drug: Second Line ITP agents
    Sponsors:   Children's Hospital Boston;   Terrana ITP Research Fund
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsor:   Onyx Therapeutics, Inc.
    Recruiting - verified March 2015

  • Conditions:   Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
    Interventions:   Drug: Momelotinib;   Drug: Ruxolitinib;   Drug: Placebo to match momelotinib;   Drug: Placebo to match ruxolitinib
    Sponsor:   Gilead Sciences
    Recruiting - verified July 2015

  • Condition:   Postpartum Hemorrhage
    Intervention:   Drug: Tranexamic Acid
    Sponsor:   Brigham and Women's Hospital
    Recruiting - verified January 2015

  • Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
    Sponsors:   Dana-Farber Cancer Institute;   Novartis
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Fenofibrate
    Sponsor:   University of Miami
    Recruiting - verified February 2015

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Placebo;   Drug: Dexamethasone
    Sponsors:   Pharmacyclics;   Janssen Research & Development, LLC;   Onyx Therapeutics, Inc.
    Recruiting - verified May 2014

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Smac Mimetic LCL161;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
    Intervention:   Biological: Pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified August 2015

  • Conditions:   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   ADA-SCID;   Adenosine Deaminase Deficiency;   Wiskott- Aldrich Syndrome;   Primary Immunodeficiencies;   Severe Combined Immune Deficiency
    Intervention:  
    Sponsors:   National Human Genome Research Institute (NHGRI);   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting - verified April 2015

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: bortezomib;   Drug: lenalidomide;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsor:   Celgene Corporation
    Recruiting - verified August 2015

  • Conditions:   Relapsed Multiple Myeloma;   End-stage Renal Disease
    Intervention:   Drug: Carfilzomib
    Sponsor:   Onyx Therapeutics, Inc.
    Recruiting - verified February 2015

  • Conditions:   Lymphoid Malignancies;   Multiple Myeloma;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
    Interventions:   Drug: Pralatrexate;   Drug: Romidepsin
    Sponsor:   Jennifer Amengual
    Recruiting - verified March 2015

  • Condition:   Thrombotic Thrombocytopenic Purpura
    Intervention:   Biological: Octaplas
    Sponsor:   Octapharma
    Not yet recruiting - verified November 2014

  • Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Radiation: Total-Body Irradiation;   Drug: Melphalan;   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Immune Thrombocytopenia;   Chemotherapy Induced Thrombocytopenia;   Myelodysplasia Related Thrombocytopenia;   Aplastic Anaemia Related Thrombocytopenia
    Intervention:   Other: Full blood count with extended platelet parameters
    Sponsor:   Beth Israel Medical Center
    Recruiting - verified March 2015

  • Conditions:   Single Umbilical Cord Blood Transplantation;   Non-myeloablative Conditioning;   Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Marginal Zone Lymphoma;   Follicular Lymphomas;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Mantle-cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Prolymphocytic Leukemia
    Intervention:   Drug: HSC835
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified July 2015

  • Conditions:   Polycythemia Vera;   Essential Thrombocythemia
    Intervention:   Procedure: Blood specimen
    Sponsors:   Icahn School of Medicine at Mount Sinai;   The Leukemia and Lymphoma Society
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma (MM)
    Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Lenalidomide
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified July 2015

  • Conditions:   Coagulopathy;   Mesothelioma
    Intervention:   Procedure: Blood draw for TEG analysis
    Sponsor:   Brigham and Women's Hospital
    Recruiting - verified January 2015

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman Diamond Syndrome;   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Chediak Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia;   Hemophagocytic Lymphohistiocytosis
    Interventions:   Drug: 4 doses of abatacept;   Drug: 6 doses of abatacept
    Sponsor:   Emory University
    Recruiting - verified April 2015

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Condition:   Relapsed and/or Relapsed-refractory Multiple Myeloma
    Interventions:   Drug: Melflufen;   Drug: Dexamethasone
    Sponsor:   Oncopeptides AB
    Recruiting - verified April 2015

  • Condition:   Cancer of Kidney
    Intervention:   Device: Microwave pre-coagulation
    Sponsor:   University of Wisconsin, Madison
    Recruiting - verified August 2015

  • Condition:   Hemophilia A
    Intervention:   Biological: PEGylated Recombinant factor VIII (rFVIII)
    Sponsors:   Baxalta US Inc.;   Baxter Innovations GmbH
    Recruiting - verified May 2015

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Intraocular Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Drug: Romidepsin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Treatment with NY-ESO-1c259-modified T cells
    Sponsor:   Adaptimmune
    Recruiting - verified June 2015

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Germ Cell Neoplasms;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immunodeficiency Diseases
    Intervention:  
    Sponsor:   Comprehensive Cancer Center of Wake Forest University
    Recruiting - verified January 2014

  • Condition:   Asymptomatic Multiple Myeloma
    Intervention:   Drug: ENK Cell Infusion
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified July 2015

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Intervention:   Drug: Cabozantinib (XL184)
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Exelixis
    Recruiting - verified May 2015

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: ixazomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Heart Failure;   Respiratory Failure
    Intervention:  
    Sponsors:   University of California, San Francisco;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified May 2015

  • Condition:   Myeloma
    Intervention:   Drug: Lenalidomide, Dexamethasone, and MEDI-551
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   MedImmune LLC
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Interventions:   Biological: aMIL;   Drug: No aMIL
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   The Leukemia and Lymphoma Society
    Recruiting - verified June 2015

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
    Sponsors:   University of Iowa;   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: IXAZOMIB + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Conditions:   Severe Combined Immunodeficiency (SCID);   Immunodeficiency With Predominant T-cell Defect, Unspecified;   Severe Chronic Neutropenia;   Chronic Granulomatous Disease (CGD);   Hyper IgE Syndromes;   Hyper IgM Deficiencies;   Wiskott-Aldrich Syndrome;   Mendelian Susceptibility to Mycobacterial Disease;   Common Variable Immune Deficiency (CVID)
    Intervention:   Biological: CD3/CD19 negative allogeneic hematopoietic stem cells
    Sponsor:   University of Pittsburgh
    Recruiting - verified December 2014

  • Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carfilzomib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsors:   Bristol-Myers Squibb;   AbbVie
    Recruiting - verified July 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Trauma;   Hemorrhagic Shock
    Interventions:   Biological: Type AB plasma;   Drug: Crystalloid fluid (standard of care for resuscitation)
    Sponsors:   Denver Health and Hospital Authority;   U.S. Army Medical Research and Materiel Command;   University of Colorado, Denver
    Recruiting - verified May 2015

  • Conditions:   Primary Liver Cancer;   SCLC;   Lymphoma;   Melanoma;   ALL;   CLL;   Multiple Myeloma;   MDS
    Intervention:   Drug: MRX34
    Sponsors:   Mirna Therapeutics, Inc.;   Cancer Prevention Research Institute of Texas
    Recruiting - verified July 2015

  • Conditions:   Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Plasma Cell Myeloma
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Biological: WT1 Analog Peptide Vaccine;   Biological: Sargramostim (GM-CSF);   Drug: lenalidomide
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified July 2015

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: dexamethasone;   Drug: carfilzomib;   Drug: lenalidomide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
    Intervention:   Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    Sponsor:   Washington University School of Medicine
    Recruiting - verified December 2014

  • Conditions:   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: alisertib;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsors:   Kristie Blum;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2015

  • Conditions:   Nephrotic Syndrome;   Hyperlipidemia
    Intervention:   Drug: Pravastatin
    Sponsor:   University of North Carolina, Chapel Hill
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Acupuncture;   Procedure: Sham acupuncture
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified April 2015

  • Conditions:   Multiple Myeloma;   Disease of the Marrow;   Osteoporosis
    Intervention:  
    Sponsor:   New York University School of Medicine
    Recruiting - verified January 2015

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Epstein-Barr Virus Infection;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: brentuximab vedotin;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsors:   Northwestern University;   Seattle Genetics, Inc.
    Recruiting - verified April 2015

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
    Intervention:   Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
    Sponsors:   John Mascarenhas;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Incyte Corporation;   Novartis
    Recruiting - verified October 2014

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Pomalidomide
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Condition:   Myeloma
    Interventions:   Drug: Minocycline;   Other: Placebo;   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Cavernous Angioma, Familial;   Cerebral Cavernous Malformations;   Cerebral Cavernous Hemangioma
    Intervention:   Drug: Simvastatin
    Sponsors:   University of New Mexico;   National Institute of Neurological Disorders and Stroke (NINDS);   University of California, San Francisco
    Recruiting - verified May 2015

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified August 2015

  • Conditions:   Multiple Myeloma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Romidepsin;   Drug: Lenalidomide
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Saint Francis/Mount Sinai Regional Cancer Center;   Weill Medical College of Cornell University;   University of Nebraska;   Celgene Corporation;   Biologics, Inc.
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: busulfan;   Drug: melphalan;   Drug: fludarabine;   Biological: anti-thymocyte globulin (ATG);   Procedure: a T cell depleted stem cell transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified July 2015

  • Condition:   Relapsed/Refractory Multiple Myeloma
    Interventions:   Drug: ABT-199;   Drug: bortezomib;   Drug: dexamethasone
    Sponsors:   AbbVie (prior sponsor, Abbott);   Genentech, Inc.
    Recruiting - verified August 2015

  • Conditions:   Chronic Kidney Disease;   Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Chronic Myelogenous Leukemia (CML);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkin's Lymphoma (NHL);   Hodgkin Disease;   Multiple Myeloma;   Myelodysplastic Syndrome (MDS);   Aplastic Anemia;   AL Amyloidosis;   Diamond Blackfan Anemia;   Myelofibrosis;   Myeloproliferative Disease;   Sickle Cell Anemia;   Autoimmune Diseases;   Thalassemia
    Intervention:   Procedure: Haploidentical Bone Marrow/Kidney
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Drug: dexamethasone;   Drug: SAR650984
    Sponsor:   Sanofi
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Procedure: stem cell;   Drug: Dexamethasone;   Drug: Clarithromycin
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Celgene Corporation;   Weill Medical College of Cornell University;   North Shore University Hospital;   Rutgers Cancer Institute of New Jersey;   State University of New York - Upstate Medical University
    Recruiting - verified May 2015

  • Conditions:   Multiple Myeloma;   Lymphoma
    Intervention:   Drug: CUDC-907
    Sponsors:   Curis, Inc.;   The Leukemia and Lymphoma Society
    Recruiting - verified April 2015

  • Conditions:   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Biological: Palifermin;   Biological: Lupron;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total-Body Irradiation (TBI);   Drug: Thiotepa;   Drug: Cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Swedish Orphan Biovitrum
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
    Sponsor:   Celgene Corporation
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bendamustine;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsors:   Cristina Gasparetto;   Celgene Corporation
    Recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Velcade;   Drug: Cyclophosphamide;   Drug: Revlimid
    Sponsors:   Duke University;   Millennium Pharmaceuticals, Inc.;   Duke Cancer Institute
    Recruiting - verified May 2015

  • Conditions:   Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Oncology;   Oncology Patients;   Tumors;   Glioblastoma;   Multiple Myeloma
    Intervention:   Drug: AMG 232
    Sponsor:   Amgen
    Recruiting - verified June 2015

  • Condition:   Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Melphalan;   Procedure: NK Cell Infusion;   Procedure: Stem Cell Infusion;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified June 2015

  • Condition:   Severe Hemophilia A
    Intervention:   Biological: Human cl rhFVIII
    Sponsor:   Octapharma
    Recruiting - verified May 2015

  • Condition:   Recurrent Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: DKN-01 300 mg;   Drug: DKN-01 600 mg;   Drug: Standard of Care
    Sponsor:   HealthCare Pharmaceuticals, Inc.
    Recruiting - verified October 2014

  • Condition:   Relapsed/Refractory Multiple Myeloma
    Intervention:   Drug: ABT-199
    Sponsors:   AbbVie (prior sponsor, Abbott);   Genentech, Inc.
    Recruiting - verified August 2015

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: brentuximab vedotin;   Other: laboratory biomarker analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Relapse Multiple Myeloma;   Refractory Multiple Myeloma
    Intervention:   Drug: Carfilzomib
    Sponsors:   Ajai Chari;   Onyx Pharmaceuticals
    Recruiting - verified October 2014

  • Condition:   Multiple Sclerosis
    Intervention:  
    Sponsor:   Bastyr University
    Recruiting - verified April 2015

  • Condition:   Hemophilia B
    Intervention:   Biological: AskBio009
    Sponsor:   Baxalta US Inc.
    Recruiting - verified April 2015

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: indium In 111 anti-CD45 monoclonal antibody BC8;   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Conditions:   Hodgkin Disease;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Lymphomatoid Granulomatosis;   Leukemia-Lymphoma, Adult T-Cell
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Multiple Myeloma;   Peripheral Neuropathy
    Intervention:  
    Sponsors:   Oncotherapeutics;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified April 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Subcutaneous bortezomib
    Sponsors:   Oncotherapeutics;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2014

  • Conditions:   Multiple Myeloma;   Plasma Cell Myeloma
    Interventions:   Biological: elotuzumab;   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Bristol-Myers Squibb
    Recruiting - verified March 2015

  • Condition:   Menstrual Cycle and Uterine Bleeding Disorders
    Interventions:   Drug: Estradiol;   Drug: Lysteda
    Sponsors:   Kay I Waud MD PhD;   American College of Obstetricians and Gynecologists
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: pomalidomide;   Drug: carfilzomib;   Drug: dexamethasone
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: ASP7487, Velcade, Dexamethasone
    Sponsors:   University Health Network, Toronto;   Multiple Myeloma Research Consortium;   Astellas Pharma Inc
    Recruiting - verified January 2015

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Busulfan;   Drug: Fludarabine  phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Panobinostat, Lenalidomide and Dexamethasone
    Sponsors:   Ajai Chari;   Novartis Pharmaceuticals
    Recruiting - verified October 2014

  • Condition:   Thermal Burns
    Intervention:  
    Sponsors:   Medstar Research Institute;   Department of Defense
    Recruiting - verified May 2015

  • Conditions:   Severe Sepsis;   Coagulopathy
    Interventions:   Drug: ART-123;   Drug: Placebo
    Sponsor:   Asahi Kasei Pharma America Corporation
    Recruiting - verified July 2015

  • Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Lymphoid Leukemia
    Interventions:   Drug: Dasatinib;   Other: laboratory biomarker analysis
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Non-Hodgkin's Lymphoma;   Multiple;   Mycosis Fungoides;   Hodgkin's Lymphoma;   Multiple Myeloma
    Intervention:   Drug: Dasatinib
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Von Willebrand Disease
    Intervention:   Other: Patients using wilate as standard of care
    Sponsor:   Octapharma
    Recruiting - verified July 2014

  • Conditions:   Traumatic Brain Injury;   Coagulation Disorder
    Intervention:  
    Sponsor:   University of California, San Diego
    Recruiting - verified May 2015

  • Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Intervention:   Other: Bortezomib
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified October 2014

  • Conditions:   Congenital Fibrinogen Deficiency;   Afibrinogenemia
    Interventions:   Biological: Octafibrin  - (Factor I concentrate);   Biological: Haemocomplettan/Riastap (Factor I concentrate)
    Sponsor:   Octapharma
    Recruiting - verified March 2015

  • Conditions:   Multiple Myeloma;   Renal Impairment
    Interventions:   Drug: 4 mg Oral POM + 40 mg Oral DEX;   Drug: 2 mg Oral POM + 40 mg Oral DEX
    Sponsor:   Celgene Corporation
    Recruiting - verified May 2015

  • Condition:   Hemophilia A
    Intervention:  
    Sponsors:   Emory University;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Revlimid;   Drug: Dexamethasone
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myeloproliferative Diseases;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
    Interventions:   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified August 2015

  • Conditions:   Chronic Lymphocytic Leukemia;   Lymphoma;   Multiple Myeloma
    Intervention:   Drug: Plerixafor
    Sponsor:   Tufts Medical Center
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: BT062 , intravenous administration
    Sponsors:   Biotest Pharmaceuticals Corporation;   Biotest
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Dexamethasone
    Sponsors:   Emory University;   Multiple Myeloma Research Consortium;   Novartis;   Onyx Therapeutics, Inc.
    Recruiting - verified March 2015

  • Condition:   Thrombotic Thrombocytopenic Purpura
    Intervention:   Biological: rituximab
    Sponsor:   J. Evan Sadler, M.D., Ph.D.
    Recruiting - verified December 2014

  • Conditions:   Plasma Cell Myeloma;   Multiple Myeloma
    Interventions:   Drug: Filgrastim;   Drug: Plerixafor;   Procedure: Apheresis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Pegylated Liposomal Doxorubicin (PLD);   Drug: Dexamethasone
    Sponsors:   Oncotherapeutics;   Celgene Corporation
    Recruiting - verified April 2015

  • Conditions:   Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Diffuse Large B-Cell Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Diffuse Large B -Cell Lymphoma;   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Stage I Adult Hodgkin Lymphoma;   Stage I Aggressive Adult Non-Hodgkin Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Diffuse Large B-Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma;   Stage II Contiguous Mantle Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Aggressive Adult Non-Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Diffuse Large B-Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Aggressive Adult Non-Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Diffuse Large B-Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Atorvastatin Calcium;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma, Neoplasms
    Interventions:   Drug: cetuximab;   Drug: vemurafenib [Zelboraf];   Drug: vemurafenib [Zelboraf]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2015

  • Conditions:   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Intervention:   Biological: therapeutic allogeneic lymphocytes
    Sponsors:   Robert Lowsky;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: TH-302;   Drug: TH-302;   Drug: TH-302 and bortezomib
    Sponsor:   Threshold Pharmaceuticals
    Recruiting - verified May 2015

  • Conditions:   Congenital Bleeding Disorder;   Haemophilia A
    Intervention:   Drug: turoctocog alfa
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified July 2015

  • Conditions:   Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Congenital Bleeding Disorder;   Haemophilia A
    Intervention:   Drug: turoctocog alfa pegol
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified July 2015

  • Conditions:   Solid Tumors;   Lymphoma;   Multiple Myeloma
    Intervention:   Drug: CS-7017 and Bexarotene
    Sponsors:   Georgetown University;   Daiichi Sankyo Inc.
    Recruiting - verified August 2014

  • Condition:   High-risk Smoldering Multiple Myeloma
    Interventions:   Drug: Siltuximab;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Simvastatin and zoledronic acid
    Sponsors:   James Graham Brown Cancer Center;   University of Louisville
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsors:   Academic Myeloma Consortium;   Criterium Inc.;   Onyx Pharmaceuticals;   Celgene Corporation
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: LGH447;   Drug: midazolam
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsors:   Multiple Myeloma Research Foundation;   Translational Genomics Research Institute, Phoenix, Arizona.;   Spectrum Health Hospitals;   Van Andel Research Institute
    Recruiting - verified January 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Fludarabine monophosphate, melphalan, Bortezomib
    Sponsor:   Hackensack University Medical Center
    Recruiting - verified August 2015

  • Condition:   Myeloma
    Interventions:   Drug: Panobinostat;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Behavioral: Symptom Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   Novartis
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Intervention:   Biological: CD3/CD28
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified January 2015

  • Condition:   Multiple Myeloma
    Intervention:   Procedure: Blood draws
    Sponsor:   Beth Israel Deaconess Medical Center
    Recruiting - verified May 2015

  • Conditions:   Solid Tumors;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Glioblastoma Multiforme;   Oligodendroglioma;   Hepatocellular Carcinoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: CC-122;   Drug: CC-122;   Drug: CC-122
    Sponsor:   Celgene Corporation
    Recruiting - verified August 2015

  • Conditions:   Primary Myelofibrosis;   Post-Polycythemic Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
    Intervention:   Drug: NS-018
    Sponsor:   NS Pharma, Inc.
    Recruiting - verified October 2014

  • Conditions:   Myelofibrosis;   Gaucher Disease;   Pulmonary Fibrosis;   Hermansky-Pudlak Syndrome (HPS);   Cancer
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting - verified January 2015

  • Condition:   Coagulation Defects
    Interventions:   Biological: Spray-dried S/D-treated Plasma;   Drug: Spray-dried S/D-treated plasma;   Biological: Spray-dried S/D-treated Plasma;   Biological: Spray-dried S/D-treated Plasma;   Biological: Spray-dried S/D-treated Plasma
    Sponsor:   Entegrion, Inc.
    Recruiting - verified August 2015

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia (CML);   Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission;   Chronic Lymphocytic Leukemia (CLL);   Multiple Myeloma (MM);   Myelodysplastic Syndrome (MDS);   Myeloproliferative Disorders
    Interventions:   Drug: POL6326;   Procedure: Leukapheresis;   Procedure: PBSC Transplant
    Sponsor:   Polyphor Ltd.
    Recruiting - verified July 2015

  • Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Acute Myelogenous Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Radiation: Total Body Radiation;   Biological: Cord Blood
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified March 2015

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: plerixafor;   Biological: filgrastim;   Drug: etoposide;   Procedure: leukapheresis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Conditions:   Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
    Intervention:   Procedure: tissue banking
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting - verified June 2015

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Thomas Jefferson University
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan;   Drug: Bortezomib
    Sponsor:   Hackensack University Medical Center
    Recruiting - verified August 2015

  • Condition:   Myeloma
    Interventions:   Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim
    Sponsors:   M.D. Anderson Cancer Center;   Array BioPharma;   Onyx Therapeutics, Inc.
    Recruiting - verified April 2015

  • Conditions:   Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
    Intervention:   Drug: Ruxolitinib (INCB018424)
    Sponsor:   Incyte Corporation
    Recruiting - verified February 2015

  • Conditions:   Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
    Interventions:   Drug: Denosumab;   Drug: Zoledronic acid
    Sponsors:   Amgen;   Daiichi Sankyo Inc.
    Recruiting - verified August 2015

  • Conditions:   Hodgkin's Lymphoma;   Leukemia;   Myelodysplastic Syndrome(MDS);   Multiple Myeloma;   Non Hodgkin's Lymphoma
    Intervention:   Procedure: Bone Marrow Transplant
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified June 2015

  • Conditions:   Hematological Malignancies;   Leukemia;   Lymphoma;   Multiple Myeloma;   Hodgkin's Disease
    Intervention:   Device: Matched Sibling Allogeneic Transplantation
    Sponsor:   Thomas Jefferson University
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: ACY-1215
    Sponsors:   Acetylon Pharmaceuticals Incorporated;   The Leukemia and Lymphoma Society
    Recruiting - verified June 2015

  • Condition:   Haemophilia A
    Intervention:   Biological: Recombinant Factor VIII (BAY81-8973)
    Sponsor:   Bayer
    Recruiting - verified August 2015

  • Condition:   Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Panobinostat
    Sponsors:   M.D. Anderson Cancer Center;   Novartis;   Onyx Therapeutics, Inc.
    Recruiting - verified July 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
    Sponsor:   Hackensack University Medical Center
    Recruiting - verified August 2015

  • Conditions:   Patients Undergoing Routine Health Care;   Heart Diseases;   Inflammatory Bowel Diseases;   Autoimmune Disease;   Inflammatory Disease;   Blood Coagulation Disorders;   Hepatitis C;   Non-Metastatic Neoplasm
    Intervention:  
    Sponsor:   University of Chicago
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Eltrombopag
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified August 2015

  • Conditions:   Hereditary Spherocytosis;   Idiopathic Thrombocytopenic Purpura
    Interventions:   Procedure: Single Incision Splenectomy;   Procedure: Laparoscopic Splenectomy
    Sponsor:   Children's Mercy Hospital Kansas City
    Recruiting - verified February 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: panobinostat;   Other: laboratory biomarker analysis;   Genetic: western blotting;   Genetic: DNA analysis;   Other: flow cytometry;   Other: pharmacological study;   Other: immunohistochemistry staining method
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
    Interventions:   Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
    Sponsors:   Ronald Hoffman;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Roche Pharma AG;   QIAGEN Marseille
    Recruiting - verified June 2015

  • Conditions:   High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
    Interventions:   Drug: PEGASYS;   Drug: Aspirin
    Sponsors:   Ronald Hoffman;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Roche Pharma AG;   QIAGEN Marseille
    Recruiting - verified June 2015

  • Conditions:   Thrombotic Thrombocytopenic Purpura;   Congenital Thrombotic Thrombocytopenic Purpura;   Familial Thrombotic Thrombocytopenic Purpura;   Thrombotic Thrombocytopenic Purpura, Congenital;   Upshaw-Schulman Syndrome
    Intervention:   Other: Observation
    Sponsors:   University Hospital Inselspital, Berne;   Swiss National Science Foundation;   Mach-Gaensslen Foundation Switzerland;   Baxter Healthcare Corporation
    Recruiting - verified February 2015

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: sirolimus;   Drug: cyclosporine;   Drug: mycophenolate mofetil
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: carfilzomib;   Drug: pegylated liposomal doxorubicin (PLD);   Drug: Dexamethasone
    Sponsor:   Washington University School of Medicine
    Recruiting - verified May 2015

  • Conditions:   Multiple Myeloma;   Auto Stem Cell Transplant
    Intervention:   Drug: Bortezomib
    Sponsor:   Hackensack University Medical Center
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Adoptive Immunotherapy;   Biological: Rapamycin-Generated Autologous Th1/Tc1 Cells
    Sponsors:   National Cancer Institute (NCI);   Hackensack University Medical Center
    Recruiting - verified February 2015

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: sirolimus;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Lymphoma;   Lymphoplasmacytic Lymphoma;   Waldenström Macroglobulinemia
    Intervention:   Biological: DNA Vaccine
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified June 2015

  • Conditions:   AML;   ALL;   Blast Crisis;   MDS;   Multiple Myeloma
    Interventions:   Drug: TG02 citrate;   Drug: Carfilzomib;   Drug: Dexamethasone
    Sponsor:   Tragara Pharmaceuticals, Inc.
    Recruiting - verified April 2015

  • Conditions:   Lymphoma;   Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Pomalidomide
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bendamustine;   Drug: Doxorubicin;   Drug: Bortezomib;   Drug: Bendamustine;   Drug: Filgrastim
    Sponsors:   Sherif Farag, MB, BS;   Hoosier Cancer Research Network;   Cephalon
    Recruiting - verified April 2015

  • Conditions:   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
    Intervention:  
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified August 2015

  • Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
    Interventions:   Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Condition:   Hereditary Hemorrhagic Telangiectasia
    Intervention:  
    Sponsors:   St. Michael's Hospital, Toronto;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting - verified May 2015

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: dexamethasone;   Other: DNA methylation analysis;   Other: gene expression analysis;   Other: bone marrow aspiration;   Other: immunohistochemistry staining method;   Other: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide plus Melphalan during autologous stem cell transplantation;   Drug: Lenalidomide maintenance
    Sponsors:   Attaya Suvannasankha;   Celgene Corporation
    Recruiting - verified January 2015

  • Conditions:   Chronic Myeloproliferative Disorders;   Cognitive/Functional Effects;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:  
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Multiple Myeloma;   Leukemia;   MGUS;   MBL
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: busulfan, melphalan and fludarabine;   Drug: busulfan, melphalan and fludarabine
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Otsuka America Pharmaceutical;   Ludwig Institute for Cancer Research
    Recruiting - verified June 2015

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified March 2015

  • Condition:   Purpura, Thrombocytopaenic, Idiopathic
    Intervention:   Drug: Eltrombopag
    Sponsor:   GlaxoSmithKline
    Recruiting - verified May 2015

  • Condition:   Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
    Intervention:   Biological: Romiplostim
    Sponsor:   Amgen
    Recruiting - verified April 2015

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1;   Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Burkitt Lymphoma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Melphalan;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Hemophilia B
    Intervention:   Genetic: Gene Transfer
    Sponsors:   St. Jude Children's Research Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Hemophilia of Georgia, Inc.;   Children's Hospital of Philadelphia
    Recruiting - verified August 2015

  • Condition:   Thrombotic Thrombocytopenic Purpura
    Intervention:   Drug: Danazol
    Sponsors:   Beth Israel Medical Center;   Icahn School of Medicine at Mount Sinai
    Recruiting - verified July 2015

  • Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Device: 3'-deoxy-3'-[18F]fluorothymidine
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   B-Cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia
    Intervention:  
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified September 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Plerixafor (AMD3100);   Drug: bortezomib
    Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Genzyme, a Sanofi Company;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified August 2015

  • Condition:   Multiple Myeloma
    Interventions:   Genetic: clonality analysis;   Genetic: polymerase chain reaction;   Genetic: protein analysis;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis;   Procedure: fluorescence spectroscopy;   Procedure: quality-of-life assessment
    Sponsor:   Boston Medical Center
    Recruiting - verified January 2015

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Menkes Disease;   Occipital Horn Syndrome;   Unexplained Copper Deficiency
    Intervention:   Drug: Copper Histidine
    Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Center for Complementary and Integrative Health (NCCIH)
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem cell transplant x 1 or x 2;   Drug: lenalidomide and dexamethasone
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Tufts Medical Center;   Lahey Clinic
    Recruiting - verified May 2015

  • Conditions:   Multiple Myeloma;   Plasma Cell Neoplasm
    Interventions:   Drug: Group A=30-60 CrCl (mL/min);   Drug: Group B=CrCL<30 mL/min not on dialysis;   Drug: Group C=CrCL<30 mL/min and on dialysis
    Sponsors:   PrECOG, LLC.;   Celgene Corporation
    Recruiting - verified June 2015

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma;   Previously Treated Myelodysplastic Syndrome;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia;   Refractory Plasma Cell Myeloma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Wayne D. Kuni and Joan E. Kuni Foundation
    Recruiting - verified May 2015

  • Conditions:   Wiskott-Aldrich Syndrome (WAS);   X-linked Thrombocytopenia
    Intervention:   Drug: Interleukin-2
    Sponsors:   Soma Jyonouchi;   Texas Children's Hospital
    Recruiting - verified June 2015

  • Condition:   HIV
    Intervention:  
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified August 2015

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Indolent Non-Hodgkin Lymphoma;   Malignant Lymphoma, Large Cell Type;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Umbilical Cord Blood Transplantation;   Radiation: Total-Body Irradiation;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Aggressive Non-Hodgkin Lymphoma;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   Burkitt Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia With Excess Blasts
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Condition:   Multiple Myeloma
    Interventions:   Biological: filgrastim;   Drug: melphalan;   Procedure: Stem Cell Infusion
    Sponsor:   Boston Medical Center
    Recruiting - verified January 2015

  • Conditions:   Lymphoma, Non-Hodgkin;   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-Cell;   Monoclonal B-Cell Lymphocytosis;   Multiple Myeloma
    Intervention:  
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2014

  • Conditions:   Multifocal Lymphangioendotheliomatosis With Thrombocytopenia;   Cutaneovisceral Angiomatosis With Thrombocytopenia;   Vascular Anomaly With Thrombocytopenia;   Hemangiomas
    Intervention:   Other: no intervention
    Sponsor:   Medical College of Wisconsin
    Recruiting - verified November 2014

  • Conditions:   Lymphoma;   Leukemia;   Multiple Myeloma;   Colon Cancer;   Renal Cancer
    Intervention:  
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Montefiore Medical Center;   St. Jude Children's Research Hospital
    Recruiting - verified August 2015

  • Condition:   Hemophilia A
    Interventions:   Biological: Moroctocog alfa (AF-CC);   Biological: Moroctocog alfa (AF-CC)
    Sponsor:   Pfizer
    Recruiting - verified August 2015

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Disease;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Cyclosporine;   Drug: Allogenic stem cell transplant (ASCT);   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Biological: Alemtuzumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Idiopathic Thrombocytopenic Purpura
    Intervention:   Biological: IGIV3I Grifols 10%
    Sponsor:   Grifols Biologicals Inc.
    Recruiting - verified May 2015

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Pharmacological Study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Essential Thrombocythemia;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified June 2015

  • Conditions:   Autoimmune Pancytopenia;   Autoimmune Lymphoproliferative Syndrome (ALPS);   Evans Syndrome;   Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune;   Autoimmune Neutropenia;   Lupus Erythematosus, Systemic;   Inflammatory Bowel Disease;   Rheumatoid Arthritis
    Intervention:   Drug: sirolimus
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting - verified April 2015

  • Condition:   Hemophilia A
    Interventions:   Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM);   Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
    Sponsor:   Baxalta US Inc.
    Recruiting - verified April 2015

  • Conditions:   Leukemia;   Multiple Myeloma;   Hodgkin Lymphoma;   Lymphoma, Non-Hodgkin
    Intervention:  
    Sponsors:   National Cancer Institute (NCI);   Lymphoma/Leukemia Molecular Profiling Project (LLMPP)
    Recruiting - verified December 2014

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified February 2015

  • Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total body irradiation;   Drug: filgrastim
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2015

  • Condition:   Glanzmann Thrombasthenia
    Intervention:  
    Sponsors:   Rockefeller University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2015

  • Conditions:   Blood Coagulation Disorders, Inherited;   Thrombotic Disorder
    Intervention:  
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting - verified June 2015

  • Condition:   Hemophilia A
    Intervention:  
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting - verified June 2015

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2015

  • Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2015

  • Conditions:   Accelerated Phase of Disease;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Myelodysplastic Syndrome;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase of Disease;   de Novo Myelodysplastic Syndrome;   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone Lymphoma;   Previously Treated Myelodysplastic Syndrome;   Primary Myelofibrosis;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Splenic Marginal Zone Lymphoma;   Stage II Adult Non-Contiguous Immunoblastic Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage II Marginal Zone Lymphoma;   Stage II Non-Contiguous Adult Burkitt Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: Pentostatin;   Biological: Therapeutic Allogeneic Lymphocytes;   Drug: Mycophenolate Mofetil;   Drug: Cyclosporine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Conditions:   Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Intervention:   Genetic: cytogenetic analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Conditions:   Waldenstrom Macroglobulinemia;   Chronic Lymphocytic Leukemia;   Hodgkin Disease;   NonHodgkin Lymphoma;   Mixed Lymphoproliferative Disease
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Albinism;   Intestinal Disease;   Kidney Disease;   Myocardial Disease;   Pulmonary Fibrosis
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting - verified April 2015

  • Conditions:   Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
    Intervention:   Procedure: Stem cell transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2015


PaidClinicalTrials.orgPaidClinicalTrials.org